Bleakley Financial Group LLC Sells 8,821 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Bleakley Financial Group LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,586 shares of the medical research company's stock after selling 8,821 shares during the period. Bleakley Financial Group LLC's holdings in IQVIA were worth $11,242,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its holdings in IQVIA by 19.6% in the second quarter. Parkside Financial Bank & Trust now owns 293 shares of the medical research company's stock valued at $66,000 after purchasing an additional 48 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in shares of IQVIA by 1.1% during the third quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company's stock worth $927,000 after buying an additional 50 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in IQVIA by 6.1% during the fourth quarter. Penserra Capital Management LLC now owns 971 shares of the medical research company's stock worth $198,000 after purchasing an additional 56 shares during the last quarter. Private Advisor Group LLC raised its holdings in IQVIA by 1.2% during the third quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company's stock worth $948,000 after acquiring an additional 56 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. grew its stake in shares of IQVIA by 1.6% in the third quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company's stock valued at $702,000 after buying an additional 56 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. UBS Group boosted their price objective on IQVIA from $240.00 to $300.00 and gave the stock a "buy" rating in a report on Thursday, February 15th. Guggenheim lowered IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. Citigroup upped their price target on IQVIA from $190.00 to $225.00 and gave the stock a "neutral" rating in a research note on Monday, December 11th. Robert W. Baird raised their price objective on IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a research note on Thursday, February 15th. Finally, Leerink Partnrs reiterated an "outperform" rating on shares of IQVIA in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $256.80.

IQVIA Stock Performance

Shares of NYSE IQV traded up $0.05 during mid-day trading on Monday, hitting $241.50. The stock had a trading volume of 495,439 shares, compared to its average volume of 1,002,108. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The firm has a market cap of $43.83 billion, a PE ratio of 33.13, a PEG ratio of 2.34 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The company has a 50 day moving average of $241.28 and a two-hundred day moving average of $219.79.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion during the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA's quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the business earned $2.54 earnings per share. Research analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares of the company's stock, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin C. Knightly sold 8,607 shares of the business's stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the sale, the insider now directly owns 5,251 shares of the company's stock, valued at $1,313,642.67. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.